Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases

被引:20
作者
Harano, Y
Suzuki, M
Koyama, Y
Kanda, M
Yasuda, S
Suzuki, K
Takamizawa, I
机构
[1] Koshien Univ Coll Nutr, Takarazuka, Hyogo, Japan
[2] Natl Cardiovasc Ctr, Osaka, Japan
关键词
insulin resistance; hypertension; CAD; CVD; ASO; hyperlipidemia;
D O I
10.1016/S1056-8727(01)00192-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin resistance and hyperinsulinemia ha c been observed in over 70% of the nonobese, nondiabetic Subjects with essential hypertension (HT). Alpha-1 blockers, ACE-antagonists, long-acting Ca blockers including nifedipine CR. some form of 3-blockers, tilisolor. which is reported to increase blood flow, improve insulin sensitivity when blood pressure is better controlled. Decrease of serum potassium during insulin sensitivity test and intraplatelet free Ca2+ concentration is positively and negatively correlated with insulin sensitivity,, respectively, Blood pressure is Correlated with insulin resistance, which is also observed in secondary HT. The resistance is cot-related with salt sensitivity as well as impaired nocturnal Call of blood pressure. These suggest the possible association of insulin resistance with altered intracellular cation metabolism. Insulin resistance and associated hyperinsulinemia have been observed in effort as well as vasospastic angina pectoris (VSAP), atherothrombotic cerebral infarction. and in ASO without obesity. HT. or diabetes, suggesting the resistance resulting from endothelial dysfunction. Insulin resistance has been observed in heart failure and is correlated with angiotensin II. Resistance is also observed in hypertrophic cardiomyopathy and is partially correlated with TNF-alpha. These results indicate that insulin resistance seem to be multi factorial. An effort to normalize insulin sensitivity is crucial to eliminate multiple risk factor,,, as well as to present the progression of atherosclerotic vascular lesions. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:19 / 23
页数:5
相关论文
共 10 条
[1]  
HARANO Y, 1990, PROGR OBESITY RES, P299
[2]  
HARANO Y, 1996, DIABETES, V45, P31
[3]   Modified method using a somatostatin analogue, octreotide acetate (Sandostatin(R)) to assess in vivo insulin sensitivity [J].
Ikebuchi, M ;
Suzuki, M ;
Kageyama, A ;
Hirose, J ;
Yokota, C ;
Ikeda, K ;
Shinozaki, K ;
Todo, R ;
Harano, Y .
ENDOCRINE JOURNAL, 1996, 43 (01) :125-130
[4]   Hyperbetalipoproteinemia with small low-density lipoprotein, a characteristic disorder of lipoprotein in essential hypertension [J].
Ikeda, K ;
Suzuki, M ;
Ikebuchi, M ;
Hara, Y ;
Tsushima, M ;
Yamamoto, A ;
Harano, Y .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1995, 9 (04) :227-229
[5]   HOMEOSTASIS MODEL ASSESSMENT - INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA-GLUCOSE AND INSULIN CONCENTRATIONS IN MAN [J].
MATTHEWS, DR ;
HOSKER, JP ;
RUDENSKI, AS ;
NAYLOR, BA ;
TREACHER, DF ;
TURNER, RC .
DIABETOLOGIA, 1985, 28 (07) :412-419
[6]   Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke [J].
Shinozaki, K ;
Naritomi, H ;
Shimizu, T ;
Suzuki, M ;
Ikebuchi, M ;
Sawada, T ;
Harano, Y .
STROKE, 1996, 27 (01) :37-43
[7]   INSULIN-RESISTANCE ASSOCIATED WITH COMPENSATORY HYPERINSULINEMIA AS AN INDEPENDENT RISK FACTOR FOR VASOSPASTIC ANGINA [J].
SHINOZAKI, K ;
SUZUKI, M ;
IKEBUCHI, M ;
TAKAKI, H ;
HARA, Y ;
TSUSHIMA, M ;
HARANO, Y .
CIRCULATION, 1995, 92 (07) :1749-1757
[8]  
SHINOZAKI K, 1996, DIABETES CARE, V72, P1749
[9]   Improvement of insulin resistance in essential hypertension by long-acting Ca antagonist benidipine [J].
Suzuki, M ;
Kanazawa, A ;
Hasegawa, M ;
Harano, Y .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 1999, 21 (08) :1327-1344
[10]   Evaluation of factors during OGTT to correlate insulin resistance in non-diabetic subjects [J].
Takeuchi, M ;
Kanazawa, A ;
Suzuki, M ;
Hasegawa, M ;
Kimura, Y ;
Kodama, K ;
Ryomoto, K ;
Hattori, Y ;
Harano, Y .
ENDOCRINE JOURNAL, 2000, 47 (05) :535-542